Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emcure PharmaceuticalsNSE:EMCURE +0.62%41 Buyback Yield % is -0.02 as of Jul. 24, 2026. GuruFocus rates NSE:EMCURE with a GF Score™ of 41/100. The stock has 5 warning signs investors should review. Among 290 Drug Manufacturers companies, Emcure Pharmaceuticals ranks better than 62.76% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Emcure Pharmaceuticals Buyback Yield % Related Terms
Emcure Pharmaceuticals Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Emcure Pharmaceuticals's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:EMCURE vs ZTS, UTHR: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Emcure Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emcure Pharmaceuticals Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emcure Pharmaceuticals's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Emcure Pharmaceuticals's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emcure Pharmaceuticals (NSE:EMCURE) has a Buyback Yield % of -0.02 as of Jul. 24, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Emcure Pharmaceuticals and its competitors. According to the industry distribution chart, Emcure Pharmaceuticals ranks #108 out of 290 companies in the Drug Manufacturers industry, placing it in the top 37.2%.
Is Emcure Pharmaceuticals' Buyback Yield % too high?
Emcure Pharmaceuticals' current Buyback Yield % is -0.02. Based on the distribution chart, Emcure Pharmaceuticals ranks #108 out of 290 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Emcure Pharmaceuticals has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Emcure Pharmaceuticals' Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Emcure Pharmaceuticals ranks #108 out of 290 companies for Buyback Yield %. This puts Emcure Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Emcure Pharmaceuticals and its competitors. Emcure Pharmaceuticals's current Buyback Yield % is -0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emcure Pharmaceuticals stock overvalued right now?
Emcure Pharmaceuticals (NSE:EMCURE) has a current Buyback Yield % of -0.02. The current Buyback Yield % is -0.02. Emcure Pharmaceuticals' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Emcure Pharmaceuticals (NSE:EMCURE), the current Buyback Yield % is -0.02 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics. The company operates in Derma, Women's Health, Cardiovascular, Neurology, Oncology, Vaccines, and Anti-infectives. Geographically, it operates in India, Europe, Canada, Vietnam, Dubai, and Other Countries.
41GF Score
Get the complete analysis for NSE:EMCURE
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:EMCURE has been successfully added to your 
